Heron Therapeutics (HRTX) Operating Income (2010 - 2026)
Heron Therapeutics' (HRTX) quarterly Operating Income came in at -$4.8 million in Q1 2026, down 251.08% YoY from $3.2 million in Q1 2025, and down 12639.47% on a QoQ basis from $38000.0 in Q4 2025.
Heron Therapeutics (HRTX) Operating Income (2010 - 2026) Analysis & Trends
Heron Therapeutics (HRTX) has 17 years of Operating Income data on file, last reported at -$4.8 million in Q1 2026.
- Quarterly Operating Income fell 251.08% year-over-year to -$4.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$10.5 million (down 192.42% YoY) and the FY2025 annual result came in at -$2.5 million, up 77.98% from the prior year.
- Operating Income eased to -$4.8 million in Q1 2026, from $38000.0 in the prior quarter.
- In the past five years, Operating Income ranged from a high of $4.2 million in Q4 2024 to a low of -$62.9 million in Q1 2022.
- A 5-year average of -$17.9 million and a median of -$6.4 million in 2024 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2025 — Operating Income surged 165.74% — and 2026, when it tumbled 251.08%.
- Tracing HRTX's Operating Income over 5 years: stood at -$20.4 million in 2022, then surged by 49.79% to -$10.2 million in 2023, then soared by 140.83% to $4.2 million in 2024, then plunged by 99.09% to $38000.0 in 2025, then sank by 12639.47% to -$4.8 million in 2026.
- The last three Operating Income figures came in at -$4.8 million (Q1 2026), $38000.0 (Q4 2025), and -$4.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Heron Therapeutics | 58.32 Mn | 15.65 Mn | 26.09 Mn | -2.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.04 Mn |
| Mar 31, 2026 | -4.77 Mn |
| Dec 31, 2025 | 38,000.00 |
| Sep 30, 2025 | -4.09 Mn |
| Jun 30, 2025 | -1.64 Mn |
| Mar 31, 2025 | 3.15 Mn |
| Dec 31, 2024 | 4.17 Mn |
| Sep 30, 2024 | -4.46 Mn |
| Jun 30, 2024 | -6.45 Mn |
| Mar 31, 2024 | -4.80 Mn |
| Dec 31, 2023 | -10.22 Mn |
| Sep 30, 2023 | -24.93 Mn |
| Jun 30, 2023 | -42.40 Mn |
| Mar 31, 2023 | -33.06 Mn |
| Dec 31, 2022 | -20.36 Mn |
| Sep 30, 2022 | -41.88 Mn |
| Jun 30, 2022 | -49.50 Mn |
| Mar 31, 2022 | -62.92 Mn |
| Dec 31, 2021 | -53.54 Mn |
| Sep 30, 2021 | -51.71 Mn |